Cite Filings / TRDA / 0001231919-26-001160
Feed Companies Filings Check
Sign in
Cite Filings

Pages

  • Feed
  • Companies
  • Filings
  • Check a claim

Account

  • Sign in
  • Create an account
Support (opens in new tab)
SCHEDULE 13D/A

Beneficial Ownership Report

Entrada Therapeutics, Inc. · Filed 2026-09-10 · Acc 0001231919-26-001160

Documents 1

  • SCHEDULE 13D/A Beneficial Ownership Report , xslSCHEDULE_13D_X02/primary_doc.xml

Around this filing

  • 2026-09-10 SCHEDULE 13D/A Beneficial Ownership Report
  • 2026-09-09 4 10% owner sold 259,837 shares at an average $7.33 ($1,905,768)
  • 2026-09-09 4 10% owner sold 259,837 shares at an average $7.33 ($1,905,768)
  • 2026-09-03 4 President, Research & Develop. gave up 2,079 shares (to pay taxes)
  • 2026-09-03 4 President & COO gave up 2,528 shares (to pay taxes)
  • 2026-09-03 4 Chief Financial Officer gave up 1,733 shares (to pay taxes)
  • 2025-11-18 SCHEDULE 13D/A Beneficial Ownership Report

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)
Loading xslSCHEDULE_13D_X02/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…